

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>TM</sup>

## EDITORIAL

- Antibiotic Resistance in ICUs: A Multifaceted Problem Requiring a Multifaceted Solution** 328  
ROBERT GAINES, MD

## ORIGINAL ARTICLES

- Focused Microbiological Surveillance and Gram-Negative Beta-Lactamase-Mediated Resistance in an Intensive Care Unit** 331  
E.A. BRYCE, MD, FRCP(C); J.A. SMITH, MD, FRCP(C)

- A Cluster of Fever and Hypotension on a Surgical Intensive Care Unit Related to the Contamination of Plasma Expanders by Cell Wall Products of *Bacillus stearothermophilus*** 335  
ANTONI TRILLA, MD; CARLES CODINA, DPHARM; MONTSERRAT SALLES, RN; JOSEP M. GATELL, MD; MAGDA ZARAGOZA, RN; FRANCESCO MARCO, MD; MIQUEL NAVASA, MD; JAUME MULET, MD; JOSEP RIBAS, DPHARM; MARIA T. JIMENEZ DE ANTA, MD; MIGUEL A. ASENJO, MD

- Impact of a Coordinated Tuberculosis Team in an Inner-City Hospital in New York City** 340  
BARKAT A. FAZAL, MD, MPHTM; EDWARD E. TELZAK, MD; STEVE BLUM, PHD; CATHY L. POLLARD, PA-C; MORDECAI BAR, MD; JEROME A. ERNST, MD; GLENN S. TRETT, MD

- Prevalence of PPD Positivity Among New Employees at a Hospital in New York City** 344  
KENT A. SEPKOWITZ, MD; PETER FELLA, RN; PEDRO RIVERA, RN; NERINDA VILLA, BS; JACK DEHOVITZ, MD, MPH

## PRACTICAL HEALTHCARE EPIDEMIOLOGY

- Infection Control in Long-Term-Care Facilities** 348  
LINDSAY E. NICOLLE, MD; RICHARD A. GARIBALDI, MD

## MOLECULAR HOSPITAL EPIDEMIOLOGY

- Mupirocin Resistance: Clinical and Molecular Epidemiology** 354  
SUZANNE F. BRADLEY, MD; MARY A. RAMSEY, MS; TERESA M. MORTON, PHD; CAROL A. KAUFFMAN, MD

## GLOBAL ASPECTS OF INFECTION CONTROL

- The Impact of US-Style Infection Control Programs in an Asian Country** 359  
HSIEH-SHONG LEU, MD, MSC

## SPECIAL REPORT

- Respiratory Protection Standard: Comments on OSHA's Proposed Revision** 365  
MICHAEL D. DECKER, MD, MPH

Continued inside.

# The Real Facts About Glutaraldehyde

**G**lutaraldehyde solutions have been proven effective for over 30 years. The praise in medical circles for glutaraldehyde's efficacy and safety led to quick acceptance. Glutaraldehyde's ability to reliably disinfect and sterilize medical instruments generated high confidence. And lasting confidence. Recently, however, that confidence is being questioned in certain corners. To make an informed judgement, consider the facts presented below.

## High Level Disinfection or Sterilization?

Currently, there is universal acceptance of high level disinfection for semi-critical devices such as flexible endoscopes.<sup>1</sup> This acceptance comes from both government and professional organizations, including the FDA, CDC, AORN, APIC, SGNA, and ASGE. As one group stated, "The apparent consensus is that high-level disinfection, if meticulously and consistently done, gives a high degree of patient safety; this appears to be the current standard worldwide."<sup>1</sup>

"Although the value of sterilization of semi-critical items may seem obvious, evidence that sterilization reduces the risk of infection is lacking."<sup>2</sup> The incidence of post-endoscopic infections has been estimated to be 1 in approximately 1.8 million gastrointestinal procedures.<sup>3</sup>

## Fast Acting, Compatible, Reusable and Cost Effective

Glutaraldehyde is the most commonly used liquid chemical germicide for heat-sensitive medical devices such as endoscopes. It provides *quick high level disinfection* for fast instrument turnaround time. However, manufacturers' recommendations for specific high level disinfection times vary with formulation and usage. Their complete product directions should be referred to before use.

Data from a variety of sources clearly indicate that reducing the bioburden challenge by thorough cleaning prior to high level disinfection or sterilization results in greater efficacy in less time. For example, the APIC Guideline for

Selection and Use of Disinfectants recommends 20 minutes at room temperature as the minimum exposure time for a 2% glutaraldehyde to achieve high level disinfection following cleaning. However, because manufacturers have no control over user's cleaning technique, and regulatory agencies currently do not recognize a protocol that considers the effects of cleaning on label claims<sup>4</sup>, specific label statements *cannot* be made with regard to the potential decrease in soak time and temperature following cleaning.

Glutaraldehyde can also be used to *sterilize* heat-sensitive instruments when ETO or steam sterilization is not appropriate.

Compared to other liquid chemical germicides used for high level disinfection and sterilization, alkaline glutaraldehyde has the best *compatibility with a wide range of materials*.<sup>5</sup> It is non-corrosive to instruments, including delicate endoscopic instrumentation. Furthermore, glutaraldehyde is reusable up to 14 or 28 days.<sup>6</sup> This makes it the most *cost effective* product available for high level disinfection.

In addition, glutaraldehyde may be used in automated endoscope reprocessors to reduce health care worker exposure, and reduce the variability of processing instrumentation in manual tray systems.

## Effectiveness Can Be Tested Before Each Use

Glutaraldehyde solutions *can be tested and documented* prior to each use to verify that the effective concentration is still present. This provides the end user with a margin of safety by offering a reliable way to detect unintentional dilution or contamination of the glutaraldehyde solution.

## Hard Evidence Favors Glutaraldehyde's Safety For Health Care Workers

Although glutaraldehyde can be irritating to the eyes, respiratory tract and skin, precautions can easily be undertaken to prevent these short term effects by donning appropriate protective clothing (such as high quality rubber latex gloves, protective eye wear and fluid resistant gowns) and the implementation of environmental controls that allow for adequate ventilation.<sup>7</sup> However, even upon exposure at ambient temperatures to vapor concentrations in excess of the 0.2 ppm threshold limit value, *no evidence of acute or subchronic toxicity has been found in studies on animal models*.<sup>5-7</sup>

"Glutaraldehyde does not meet the criteria for classification as a mutagen . . . [of] . . . carcinogen . . . A number of studies have no evidence of teratogenicity."<sup>8</sup> Studies conducted to date have shown glutaraldehyde *not to be a suspected carcinogen*. Although glutaraldehyde is frequently confused with formaldehyde, its chemical and toxicological properties are significantly different. OSHA, the International Agency for Research on Cancer (IARC), and the National Toxicology Program (NTP) do not list glutaraldehyde as a carcinogen.

In addition, studies conducted to date have shown glutaraldehyde *not to cause birth defects*.<sup>9,10</sup> However, as a normal precaution, pregnant women working around glutaraldehyde or other chemicals should inform their obstetricians.

## Prominent Endoscope Companies Recommend Glutaraldehyde<sup>††††</sup>

For over 30 years, prominent endoscope companies such as Olympus, Karl Storz, Stryker Endoscopy, CIRCON ACMI, Pentax and Fujinon have recommended alkaline glutaraldehyde solutions as safe to use with their delicate endoscopic instrumentation.

Third party studies confirm this recommendation. "In particular, they (glutaraldehyde solutions) are preferred for the disinfection of gastrointestinal endoscopes."<sup>10</sup>

## Glutaraldehyde Meets U.S. EPA Regulations For Non-Hazardous Waste

In compliance with U.S. EPA regulations, glutaraldehyde *may be disposed down the drain* as an ordinary domestic waste.<sup>††††</sup> Further, by the time the drain-disposed solutions reach the wastewater treatment system, they are diluted to well below 10 ppm glutaraldehyde. At this low concentration, glutaraldehyde will not have detrimental effects on functioning wastewater treatment systems.

The fact is, sewage microorganisms readily biodegrade glutaraldehyde, initially to glutaric acid, a naturally occurring compound, and then ultimately to carbon dioxide and water.

## The FDA Now Regulates Glutaraldehyde's Claims

The FDA now regulates the efficacy claims of high level disinfectants/sterilants. All manufacturers of high level disinfectants/sterilants used with medical devices are currently required to submit for 510(k) clearance with the FDA.

"Chemical germicides should be registered with the U.S. Environmental Protection Agency

and cleared for marketing by the U.S. Food and Drug Administration."<sup>11</sup> The FDA 510(k) clearance process assures that similar glutaraldehyde products will have comparable high level disinfection claims.

## Glutaraldehyde Is A Long-Running Success Story

Today, glutaraldehyde continues to pass one of the most important safety tests health care workers rely upon – the test of time.

## How To Get More Information

If you would like to learn more about glutaraldehyde, ask your Johnson & Johnson Medical, Inc. Account Manager about our educational programs, including *The Use of Glutaraldehyde in the Health Care Environment*, a videotape that allows for 2 contact hours, and *Just The Facts*, a publication that discusses important issues about high level disinfection and sterilization. If you would like technical assistance, please call 1-800-423-5850.

<sup>†</sup>Rigid endoscopes are considered to be a critical device and should be sterilized versus high level disinfection before each use, if feasible. When sterilization is not feasible, high level disinfection is acceptable. This is consistent with the Center for Disease Control guidelines for decontamination and cleaning of endoscopes, endoscopes and respiratory therapy equipment in their Department of Health and Human Services "Guidelines for Prevention and Control of Nosocomial Infection," and the "APIC: Guidelines for Selection and Use of Disinfectants."

<sup>††</sup> Provided the glutaraldehyde solution passes test strip verification of minimum effective concentration (MEC).

<sup>†††</sup> During the 1970s, the American Conference of Governmental Industrial Hygienists (ACGIH) adopted a threshold limit value (TLV) ceiling limit of 0.2 ppm of glutaraldehyde for the atmosphere in work environments. The ceiling limit may be achieved by "any reasonable combination of engineering controls, work practices and personal protective equipment." Code of Federal Regulations 29 C.F.R. 1910.1000 CH.XVII. Strive to achieve a minimum of 10 air exchanges per hour.

<sup>††††</sup> While surfactant containing glutaraldehyde solutions are NOT generally recommended for use with rigid endoscopes used in electrosurgical procedures, major scope manufacturers have found surfactant containing glutaraldehyde solutions to be compatible with their flexible endoscopes.

<sup>†††††</sup> Please note that some state and local authorities may have additional restrictions on drain disposal of specific wastes.

1. Bond WW. Center for Disease Control. Biological Indicators for a Liquid Chemical Sterilizer: A Solution to the Instrument Reprocessing Problem? *Infect Contr Hosp Epidemiol.* 1993; 14:311.

2. Rutala W. APIC Guidelines for Selection and Use of Disinfectants. *Am J Inf Contr.* p 104.

3. Transmission of Infection by Gastrointestinal Endoscopy. ASGE. 1993;39:889-896.

4. Rutala W, et al. FDA Labeling Requirements for Disinfection of Endoscopes: A Counterpoint. *Infect Contr Hosp Epidemiol.* 1995;20:1-235.

5. Bellantyne B. Review of Toxicological Studies and Human Health Effects - Glutaraldehyde, Union Carbide Corp. 1986;4-6.

6. Groetjens B, Bellantyne B, Fowler E, Snellings W. Subchronic Inhalation Study of Glutaraldehyde. *Toxicology.* 1985;9:23.

7. Kari F. National Toxicology Program Technical Report on Toxicity Studies of Glutaraldehyde - Administered by Inhalation to F344/N Rats and B6C3F Mice. *NIH Publication* 93-3548. 1993.

8. Worksafe Australia. Priority Existing Chemical Number 3, Glutaraldehyde. July, 1994.

9. Erna M, Itami T, Kawasumi N. Teratological Assessment of Glutaraldehyde in Rats by Gastric Intubation. *Teratology Letters.* 1992;63:147-153.

10. Bally J. Activity of Glutaraldehyde at Low Concentrations (1-2%) against Poliovirus and its Relevance to Gastrointestinal Endoscope Disinfection Procedures. *Applied and Environmental Microbiology.* April, 1991.

11. Proposed Recommended Practices for Chemical Disinfection. *AORN J.* 1994;464.

**Johnson & Johnson**  
**MEDICAL INC.**

© J&J INC. 1995, ARLINGTON, TEXAS 76004-3130

## EDITORIAL OFFICES

Vanderbilt University School of Medicine  
A-1131 Medical Center North  
Nashville, TN 37232-2637  
(615) 343-1095; (615) 343-1882 (FAX)  
Email: iche@mcmail.vanderbilt.edu

### EDITOR

Michael D. Decker, MD, MPH

### MANAGING EDITOR

Susan Cantrell

### STATISTICAL EDITOR

Beverly G. Mellen, PhD

### SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

### ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

### SECTION EDITORS

#### Beyond Infection Control:

#### The New Hospital Epidemiology

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

#### Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

#### Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

#### From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

#### Information Management

John A. Sellick, DO

Buffalo, New York

#### The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

#### Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

#### Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

#### Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

#### SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

#### Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

#### Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

#### Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

## EDITORIAL ADVISORY BOARD

- Jacques F. Acar, MD Paris, France  
J. Wesley Alexander, MD Cincinnati, Ohio  
Paul Arnow, MD Chicago, Illinois  
Graham A.J. Ayliffe, MD Birmingham, United Kingdom  
Neil L. Barg, MD Yakima, Washington  
Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia  
John M. Boyce, MD Providence, Rhode Island  
Professor Dr. Ilja Braveny Munich, Federal Republic of Germany  
Charles Bryan, MD Columbia, South Carolina  
Christian Brun-Buisson, MD Creteil, France  
Donald E. Craven, MD Boston, Massachusetts  
Sue Crow, MSN, RN, CIC Shreveport, Louisiana  
Franz Daschner, MD Freiburg, Federal Republic of Germany  
Leigh G. Donowitz, MD Charlottesville, Virginia  
Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin  
Theodore C. Eickhoff, MD Denver, Colorado  
Bruce Farber, MD Manhasset, New York  
Victoria J. Fraser, MD St. Louis, Missouri  
Peter C. Fuchs, MD, PhD Black Butte, Oregon  
Richard A. Garibaldi, MD Farmington, Connecticut  
Velvl Greene, PhD, MPH Beer Sheva, Israel  
Robert Gaynes, MD Atlanta, Georgia  
David W. Gregory, MD Nashville, Tennessee  
David K. Henderson, MD Bethesda, Maryland  
Peter N.R. Heseltine, MD Los Angeles, California  
Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina  
Marguerite McMillan Jackson, RN, PhD San Diego, California  
Janine Jagger, MPH, PhD Charlottesville, Virginia  
William R. Jarvis, MD Atlanta, Georgia  
Douglas S. Kernodle, MD Nashville, Tennessee  
Robert H. Latham, MD Nashville, Tennessee  
Lewis B. Lefkowitz, MD Nashville, Tennessee  
Hsieh-Shong Leu, MD, MSc Taipei, Taiwan  
Jack Levy, MD Brussels, Belgium  
Victor Lorian, MD Bronx, New York  
Dennis G. Maki, MD Madison, Wisconsin  
Professor Dr. Walter Marget Munich, Federal Republic of Germany  
William J. Martone, MD Bethesda, Maryland  
Allison McGeer, MD Toronto, Ontario, Canada  
John E. McGowan, Jr., MD Atlanta, Georgia  
Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada  
Raf Mertens, MD Brussels, Belgium  
Robert R. Muder, MD Pittsburgh, Pennsylvania  
Joseph M. Mylotte, MD, CIC Buffalo, New York  
Lindsay Nicolle, MD Winnipeg, Manitoba, Canada  
Juhani Ojajarvi, MD Helsinki, Finland  
Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota  
Jan Evans Patterson, MD San Antonio, Texas  
Sindy M. Paul, MD Trenton, New Jersey  
Michael A. Pfaller, MD Iowa City, Iowa  
Samuel Ponce de Leon, MD, MSc Mexico City, Mexico  
Isaam Raad, MD Houston, Texas  
Manfred L. Rotter, MD, DipBact Vienna, Austria  
Theodore Sacks, MD Jerusalem, Israel  
William E. Scheckler, MD Madison, Wisconsin  
Kent Sepkowitz, MD New York City, New York  
Denis Spelman, MD Prahran Victoria, Australia  
Michael L. Tapper, MD New York, New York  
Clyde Thornsberry, PhD Brentwood, Tennessee  
Professor Leonid P. Titov Minsk, Republic of Belarus  
Timothy R. Townsend, MD Millwood, Virginia  
Antoni Trilla, MD, PhD Barcelona, Spain  
Professor Wang Shu-Qun Beijing, People's Republic of China  
J. John Weems, Jr., MD Greenville, South Carolina  
Robert A. Weinstein, MD Chicago, Illinois  
Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany  
Sergio B. Wey, MD São Paulo, Brazil  
Rebecca Wurtz, MD Evanston, Illinois

### SLACK Incorporated

6900 Grove Road  
Thorofare, New Jersey 08086  
(609) 848-1000

#### Vice President/Group Publisher

Richard N. Roash

#### Publisher

John C. Carter

#### Editorial Director

Jennifer Kilpatrick

#### Production Editor

Shirley P. Strunk, ELS

#### Assistant Editor

Eileen C. Anderer

#### Circulation Manager

Lester J. Robeson, CCCC

#### Production Director

Christine Malin

#### Production Coordinator

Joanne Patterson

#### Publishing Director/ Advertising

Wayne McCourt

#### Pharmaceutical Group Sales Director

Michael LoPresti

#### Advertising Sales Representative

Jennine Kane

#### Classified/Recruitment Sales Manager

Michele Burch

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>TM</sup>

## CONTENTS

Continued from cover.

### LETTERS TO THE EDITOR

- Hepatitis C Virus Infection in Healthcare Workers (with Reply)  
Vincenzo Puro, MD; Nicola Petrosillo, MD; Giuseppe Ippolito, MD; Janine Jagger, MPH, PhD; Bruce P. Lanphear, MD, MPH;  
Calvin C. Linneman Jr., MD 324
- 
- Wound Infection Surveillance (with Reply)  
James T. Lee, MD, PhD, FACS; Deborah S. Yokoe, MD, MPH; Richard Platt, MD, MS 326

### MEDICAL NEWS

- Gina Pugliese, RN, MS 372
- 
- Community Exposure Predicts Healthcare Worker TB Skin-Test Conversion 330
- Serosurvey Finds Surgeons at Greatest Risk for Hepatitis B 334
- Community Outbreak of Legionnaires' Disease from Hospital Cooling Tower 339
- Newly Identified Virus Kills Trainer and 14 Horses in Australia 347
- New Hepatitis Viruses Identified 353
- Diphtheria Epidemic in the Newly Independent States of the Former Soviet Union 358
- Clarification of Hepatitis B Vaccine Dose for Infants 364
- FDA Approves Latex Allergy Test 372
- NIOSH Develops Videotape on Aerosol Production During Surgery 372
- Columbia/HCA Creates AIDS Network 372
- California's Orange County Reports 14% Drop in TB Cases 372
- New Russian Law Requires HIV Testing of Visitors 372
- JCAHO Backs Away from Mandatory Indicators, Invites Other Performance Measurement Systems 373
- CDC Releases Draft Guidelines for HIV Counseling and Voluntary Testing for Pregnant Women 373

### SHEA NEWS

- C. Glen Mayhall, MD 376
- 
- Healthcare Epidemiology: Measuring Performance and Implementing Improvement 376
- Dr. James Lee Heads Effort to Attract Surgeons to SHEA 376

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

**PUBLISHER:** Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

**COPYRIGHT 1995** The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher Printed in the USA.

**SUBSCRIPTIONS:** Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$95.00; Two years-\$130.00; Three years-\$160.00; Institutional: One year-\$105.00; Two years-\$145.00; Three years-\$185.00. Fellows: \$35 per year with proof of training status. Canada: \$18.00 additional each year plus 7% for Canadian Goods & Services tax; all other countries: \$36.00 additional each year Single copies of current issues may be obtained for \$15.00, United States and possessions: \$30.00 all other countries.

**REPRINTS:** All requests to reprint or use material published herein should be addressed to Dan Boyden, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Dan Boyden at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works

**CHANGE OF ADDRESS:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points. **POSTMASTER:** Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus. Current Contents---Clinical Practice, Hospital Literature Index. Cumulative Index to Nursing & Allied Health Literature. Nursing Abstracts, Laboratory Performance Information Exchange System, and RNdex Top 100.